Author:
Gatto Mariele,Kiss Emese,Naparstek Yaakov,Doria Andrea
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Stohl W: Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2013, 9: 705-720. 10.1038/nrrheum.2013.136.
2. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severe active systemic lupus erythematosus. Arthritis Rheum. 2010, 62: 222-233. 10.1002/art.27233.
3. Furie R: Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind, phase III LUNAR study. Arthritis Rheum. 2009, 60: 16-21.
4. Postal M, Costallat LT, Appenzeller S: Biological therapy in systemic lupus erythematosus. Int J Rheumatol. 2012, 2012: 578641.
5. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C: Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014, 73: 183-190. 10.1136/annrheumdis-2012-202760.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献